Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management
- PMID: 36070788
- DOI: 10.1016/S0140-6736(22)01439-8
Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management
Abstract
Acute respiratory distress syndrome (ARDS) is characterised by acute hypoxaemic respiratory failure with bilateral infiltrates on chest imaging, which is not fully explained by cardiac failure or fluid overload. ARDS is defined by the Berlin criteria. In this Series paper the diagnosis, management, outcomes, and long-term sequelae of ARDS are reviewed. Potential limitations of the ARDS definition and evidence that could inform future revisions are considered. Guideline recommendations, evidence, and uncertainties in relation to ARDS management are discussed. The future of ARDS strives towards a precision medicine approach, and the framework of treatable traits in ARDS diagnosis and management is explored.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests EAG declares funding from the Wellcome Trust for work on a study investigating acute respiratory distress syndrome (ARDS) and COVID-19 and scholarship support from the American Thoracic Society to attend an American Thoracic Society meeting. DFM declares grants as an investigator in ARDS and COVID-19 studies from Wellcome Trust, the National Institute for Health and Care Research (NIHR), Innovate UK, the Medical Research Council, Novavax, and the Northern Ireland Health and Social Care Research and Development Fund; consultancy fees unrelated to this work from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis, and Eli Lilly; and payments from GlaxoSmithKline as an educational seminar speaker. DFM is a member of the data and safety monitoring board for Vir Biotechnology and Faron Pharmaceuticals; has a patent for a novel treatment for an inflammatory disease; is a director of research for the Intensive Care Society and director of the Efficacy and Mechanism Evaluation programme for the Medical Research Council and NIHR; declares a spouse who has received grants from Wellcome Trust and the Northern Ireland Health and Social Care Research and Development Fund; consultancy fees from INSMED and from the California Institute for Regenerative Medicine, unrelated to this Series paper. CMO’K declares grants as an investigator on studies related to ARDS and COVID-19 from Wellcome Trust and the Northern Ireland Health and Social Care Research and Development Fund; consultancy fees from INSMED, unrelated to this work, and fees for participation in grant panels for the Californian Institute of Regenerative Medicine, unrelated to this Series paper. CMO’K declares a spouse who has received grants from Wellcome Trust, the Northern Ireland Health and Social Care Research and Development Fund, NIHR, Innovate UK, the Medical Research Council, and Novavax; consultancy fees unrelated to this work from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis, and Eli Lilly; payments from GlaxoSmithKline as an educational seminar speaker; is a member of the data and safety monitoring board for Vir Biotechnology, Inc, and Faron Pharmaceuticals; has a patent for a novel treatment for an inflammatory disease; is a director of research for the Intensive Care Society and Director of the Efficacy and Mechanism Evaluation programme for the Medical Research Council and NIHR.
Comment in
-
Addressing the inequity of acute respiratory distress syndrome.Lancet Respir Med. 2023 Feb;11(2):119-121. doi: 10.1016/S2213-2600(22)00352-6. Epub 2022 Sep 4. Lancet Respir Med. 2023. PMID: 36070794 No abstract available.
Similar articles
-
Comparison of the Montreux definition with the Berlin definition for neonatal acute respiratory distress syndrome.Eur J Pediatr. 2023 Apr;182(4):1673-1684. doi: 10.1007/s00431-023-04848-x. Epub 2023 Feb 3. Eur J Pediatr. 2023. PMID: 36735062
-
Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS).Adv Exp Med Biol. 2021;1304:323-331. doi: 10.1007/978-3-030-68748-9_16. Adv Exp Med Biol. 2021. PMID: 34019275
-
The Predictive Validity of the Berlin Definition of Acute Respiratory Distress Syndrome for Patients With COVID-19-Related Respiratory Failure Treated With High-Flow Nasal Oxygen: A Multicenter, Prospective Cohort Study.Crit Care Med. 2024 Jan 1;52(1):92-101. doi: 10.1097/CCM.0000000000006056. Epub 2023 Oct 16. Crit Care Med. 2024. PMID: 37846935
-
Insights Regarding the Berlin Definition of ARDS from Prospective Observational Studies.Semin Respir Crit Care Med. 2022 Jun;43(3):379-389. doi: 10.1055/s-0042-1744306. Epub 2022 Jun 9. Semin Respir Crit Care Med. 2022. PMID: 35679873 Review.
-
Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research.Eur Respir Rev. 2021 Feb 2;30(159):200317. doi: 10.1183/16000617.0317-2020. Print 2021 Mar 31. Eur Respir Rev. 2021. PMID: 33536264 Free PMC article. Review.
Cited by
-
Machine learning-based model for predicting the occurrence and mortality of nonpulmonary sepsis-associated ARDS.Sci Rep. 2024 Nov 15;14(1):28240. doi: 10.1038/s41598-024-79899-7. Sci Rep. 2024. PMID: 39548234
-
Heart-lung crosstalk in acute respiratory distress syndrome.Front Physiol. 2024 Oct 18;15:1478514. doi: 10.3389/fphys.2024.1478514. eCollection 2024. Front Physiol. 2024. PMID: 39493867 Free PMC article. Review.
-
Efficacy and safety of mesenchymal stem cell therapy for acute respiratory distress syndrome-a systematic review and meta-analysis.J Thorac Dis. 2024 Sep 30;16(9):5802-5814. doi: 10.21037/jtd-24-281. Epub 2024 Sep 26. J Thorac Dis. 2024. PMID: 39444918 Free PMC article.
-
Sivelestat protects against acute lung injury by up-regulating angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptors.J Thorac Dis. 2024 Sep 30;16(9):6182-6195. doi: 10.21037/jtd-24-1281. Epub 2024 Sep 26. J Thorac Dis. 2024. PMID: 39444885 Free PMC article.
-
Combined lung and diaphragm ultrasound predicts extubation outcomes in ARDS: a prospective study.Eur J Med Res. 2024 Oct 22;29(1):510. doi: 10.1186/s40001-024-02103-z. Eur J Med Res. 2024. PMID: 39438932 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
